ReviewOncotarget2017
Tumour-derived exosomes as a signature of pancreatic cancer - liquid biopsies as indicators of tumour progression.
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 77 citations in OpenAlex.
- Role of exosomes in cancer: from diagnosis to therapy.Discover oncology · 2025Review
- Updates on neonatal cell and novel therapeutics: Proceedings of the Second Neonatal Cell Therapies Symposium (2024).Pediatric research · 2025Article
- Hypoxia LUAD H1975 cell-derived exosomal miR-671-3p promotes angiogenesis via regulating KLF2-VEGFR2 axis.Scientific reports · 2025Article
- Peripheral Blood Extracellular Vesicle RNA Profiling: The Next Step in Cancer Liquid Biopsies.Annals of surgical oncology · 2024Article
- Quantitative Detection of Biological Nanovesicles in Drops of Saliva Using Microcantilevers.ACS applied materials & interfaces · 2024Article
- Exosomes: a potential diagnostic and treatment modality in the quest for counteracting cancer.Cellular oncology (Dordrecht, Netherlands) · 2023Review
- An update in the applications of exosomes in cancer theranostics: from research to clinical trials.Journal of cancer research and clinical oncology · 2023Review
- Evolving utility of exosomes in pancreatic cancer management.World journal of methodology · 2023Review
- Advances in the Early Diagnosis of Pancreatic Ductal Adenocarcinoma and Premalignant Pancreatic Lesions.Biomedicines · 2023Review
- A Rapid, Convergent Approach to the Identification of Exosome Inhibitors in Breast Cancer Models.Nanotheranostics · 2023Article
- Surface protein profiling of prostate-derived extracellular vesicles by mass spectrometry and proximity assays.Communications biology · 2022Article
- Article
- IgGCells · 2022Article
- Non-Invasive imaging of extracellular vesicles: Quo vaditis in vivo?Journal of extracellular vesicles · 2022Review
- Harnessing the Therapeutic Potential of Exosomes: A Novel Strategy for Anticancer and Antiviral Therapy.BioMed research international · 2022Review
- New Approaches and Biomarker Candidates for the Early Detection of Ovarian Cancer.Frontiers in bioengineering and biotechnology · 2022Article
- Exosomes as Pleiotropic Players in Pancreatic Cancer.Biomedicines · 2021Review
- Shared extracellular vesicle miRNA profiles of matched ductal pancreatic adenocarcinoma organoids and blood plasma samples show the power of organoid technology.Cellular and molecular life sciences : CMLS · 2021Article
- mRNAs in urinary nano-extracellular vesicles as potential biomarkers for non-invasive kidney biopsy.Biomedical reports · 2021Article
- Advances in the discovery of exosome inhibitors in cancer.Journal of enzyme inhibition and medicinal chemistry · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is the fourth most common cause of death due to cancer in the world. It is known to have a poor prognosis, mostly because early stages of the disease are generally asymptomatic. Progress in pancreatic cancer research has been slow, leaving several fundamental questions pertaining to diagnosis and treatment unanswered. Recent studies highlight the putative utility of tissue-specific vesicles (i.e. extracellular vesicles) in the diagnosis of disease onset and treatment monitoring in pancreatic cancer. Extracellular vesicles are membrane-limited structures derived from the cell membrane. They contain specific molecules including proteins, mRNA, microRNAs and non-coding RNAs that are secreted in the extracellular space. Extracellular vesicles can be classified according to their size and/or origin into microvesicles (~150-1000 nm) and exosomes (~40-120 nm). Microvesicles are released by budding from the plasmatic membrane, whereas exosomes are released via the endocytic pathway by fusion of multivesicular bodies with the plasmatic membrane. This endosomal origin means that exosomes contain an abundance of cell-specific biomolecules which may act as a 'fingerprint' of the cell of origin. In this review, we discuss our current knowledge in the diagnosis and treatment of pancreatic cancer, particularly the potential role of EVs in these facets of disease management. In particular, we suggest that as exosomes contain cellular protein and RNA molecules in a cell type-specific manner, they may provide extensive information about the signature of the tumour and pancreatic cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.